Lamoste, Roscia .
HRN: 25-22-68 Sex: FemalePatient Encounter
AMS Audit List
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/10/2025
CEFUROXIME 1.5GM (VIAL)
08/10/2025
08/11/2025
IVT
1.5g
Q8
LTCS
Checking Initial Appropriateness
08/11/2025
CEFUROXIME 500MG (TAB)
08/11/2025
08/17/2025
ORAL
500mg
Q12
Post CS
Checking Initial Appropriateness